The global preclinical imaging market accounted for USD 4.31 billion in 2023 and is expected to reach at USD 8.38 billion by 2034 with a CAGR of 6.23% during the forecast period 2024-2034. Rising trend of investments & funding in research & development activities, increasing advancements in technology, growing emphasis on hybrid imaging systems' development, surge in the number of clinical research organizations (CROs) & pharmaceutical companies, rising adoption of in-vivo imaging systems in preclinical research, ongoing technological advancements, and increasing introduction of innovative preclinical imaging devices are some of the key factors boosting the market growth.
Increasing introduction of innovative preclinical imaging devices is predicted to boost the market growth during the forecast period. The field of preclinical imaging has undergone significant enhancement through the integration of Artificial Intelligence (AI). AI techniques are utilized to process and analyze the vast volume of imaging data, enabling researchers to glean crucial insights and accelerate their progress. For instance, in May 2023, Royal Philips N.V. has unveiled the Philips CT 3500, an advanced high-throughput CT system designed to cater to the needs of extensive screening programs and routine radiology tasks. Leveraging artificial intelligence for operation, this system integrates various image-reconstruction and workflow-enhancing capabilities to deliver the reliability, speed, and image quality necessary for clinicians to diagnose patients with assurance and enhance profitability, even in demanding medical environments.
By product, optical imaging was the highest revenue-grossing segment in the global Preclinical Imaging Market in 2023 owing to the rising utilization of small animal imaging & its application in new drug discovery initiatives, increase in the adoption of optical preclinical imaging techniques, surge in technological progress in molecular imaging, growing demand for non-invasive small animal imaging methods in preclinical research. Additionally, multimodal is predicted to grow at the fastest CAGR during the forecast period owing to a significant increase in combining multiple imaging modalities, which enhances the accuracy & effectiveness of preclinical imaging investigations, ongoing technological advancements, heightened emphasis on creating novel therapies within preclinical research, and rising number of introductions of sophisticated devices. For instance, in May 2022, FUJIFILM VisualSonics Inc., a prominent global provider of ultrahigh frequency photoacoustic and ultrasound imaging systems, has launched the Vevo F2 multi-modal. This innovative system, tailored for preclinical applications, combines photoacoustic and ultrasound imaging capabilities. Notably, the Vevo F2 is the first system worldwide to offer a wide frequency range from ultra-high to low frequencies (71MHz-1MHz), delivering unmatched imaging flexibility for researchers.
By application, research & development was the highest revenue-grossing segment in the global Preclinical Imaging Market in 2023 owing to surge in research & development activities on numerous diseases & conditions, including Alzheimer’s disease, allergies, cancer, neurological disorders, & infectious diseases, growing collaborations among market players, increasing advancements in biomedical science, and rising development of new treatments & improving patient outcomes. Additionally, drug discovery is predicted to grow at the fastest CAGR during the forecast period. Preclinical imaging technologies play a crucial role in drug discovery by facilitating the identification and validation of new drug targets, assessing the impact of drug compounds in animal models, and streamlining drug development procedures. These technologies are extensively employed to evaluate the safety, effectiveness, and pharmacokinetics of potential drug candidates before progressing to human clinical trials. Moreover, there is an increasing emphasis on the advancement of personalized medicine in this field. For instance, in March 2023, Eli Lilly and Company revealed that solanezumab, when administered to individuals with amyloid plaque but no clinical signs of Alzheimer's disease (AD), known as the preclinical phase, using PET imaging, did not halt the progression of cognitive decline caused by AD pathology. Solanezumab specifically targets soluble amyloid beta. In participants of the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) study who received the medication, it did not eliminate plaque or prevent amyloid buildup.
By end-user, pharma and biotech companies was the highest revenue-grossing segment in the global Preclinical Imaging Market in 2023 owing to the increasing need for preclinical imaging among biotechnology firms, growing occurrence of infectious diseases, and rising efforts in developing novel therapeutics and vaccines. Additionally, research institutes is predicted to grow at the fastest CAGR during the forecast period owing to the increasing research efforts have led to a heightened demand for procedures such as CT & MRI, among others, within institutes, growing interest among researchers in utilizing imaging modalities to observe alterations in organs, tissues, cells, or at the molecular level in animals, and rising adoption of advanced devices. For instance, in June 2023, Mediso Ltd. has installed its nanoScan 7T MRI system at the University of Milano-Bicocca in Italy. This advanced MRI system features a cryogen-free superconducting magnet. Utilizing the nanoScan 7T MRI system, the University aims to analyze imaging characteristics of preclinical disease models and introduce innovative in vivo diagnostic methods.
North America region is anticipated for the highest revenue share during the forecast period owing to the presence of robust research infrastructure, skilled workforce availability, a substantial number of preclinical initiatives, increased utilization of advanced devices, and growing introduction of novel devices. For instance, in May 2023, Revvity, Inc. introduces an improved imaging lineup aimed at fostering innovation in various preclinical research fields, unveiling three new systems. Among these innovations are the advanced IVIS Spectrum 2 and IVIS SpectrumCT 2 imaging systems, which enhance versatility and sensitivity benchmarks in optical imaging for in vivo applications. Additionally, the QuantumTM GX3 microCT structural imaging solution is launched, boasting enhanced resolution and speed for both in vivo and ex vivo imaging tasks, facilitating research on disease biology and the expedited evaluation of therapeutic candidates. Additionally, Europe region is predicted to grow at fastest CAGR during the forecast period owing to the factors such as reduced research expenses, relaxed regulatory standards, heightened governmental funding for research & development initiatives, and increasing partnerships among industry participants. For instance, in April 2023, Scintica, a prominent provider of advanced preclinical research instruments, has revealed a new partnership with Bioemtech, a firm specializing in desktop SPECT, PET, and optical scanners for preclinical research applications. This collaboration seeks to broaden the accessibility of Bioemtech's preclinical instruments to researchers globally.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Increasing introduction of innovative preclinical imaging devices is predicted to boost the market growth during the forecast period. The field of preclinical imaging has undergone significant enhancement through the integration of Artificial Intelligence (AI). AI techniques are utilized to process and analyze the vast volume of imaging data, enabling researchers to glean crucial insights and accelerate their progress. For instance, in May 2023, Royal Philips N.V. has unveiled the Philips CT 3500, an advanced high-throughput CT system designed to cater to the needs of extensive screening programs and routine radiology tasks. Leveraging artificial intelligence for operation, this system integrates various image-reconstruction and workflow-enhancing capabilities to deliver the reliability, speed, and image quality necessary for clinicians to diagnose patients with assurance and enhance profitability, even in demanding medical environments.
By product, optical imaging was the highest revenue-grossing segment in the global Preclinical Imaging Market in 2023 owing to the rising utilization of small animal imaging & its application in new drug discovery initiatives, increase in the adoption of optical preclinical imaging techniques, surge in technological progress in molecular imaging, growing demand for non-invasive small animal imaging methods in preclinical research. Additionally, multimodal is predicted to grow at the fastest CAGR during the forecast period owing to a significant increase in combining multiple imaging modalities, which enhances the accuracy & effectiveness of preclinical imaging investigations, ongoing technological advancements, heightened emphasis on creating novel therapies within preclinical research, and rising number of introductions of sophisticated devices. For instance, in May 2022, FUJIFILM VisualSonics Inc., a prominent global provider of ultrahigh frequency photoacoustic and ultrasound imaging systems, has launched the Vevo F2 multi-modal. This innovative system, tailored for preclinical applications, combines photoacoustic and ultrasound imaging capabilities. Notably, the Vevo F2 is the first system worldwide to offer a wide frequency range from ultra-high to low frequencies (71MHz-1MHz), delivering unmatched imaging flexibility for researchers.
By application, research & development was the highest revenue-grossing segment in the global Preclinical Imaging Market in 2023 owing to surge in research & development activities on numerous diseases & conditions, including Alzheimer’s disease, allergies, cancer, neurological disorders, & infectious diseases, growing collaborations among market players, increasing advancements in biomedical science, and rising development of new treatments & improving patient outcomes. Additionally, drug discovery is predicted to grow at the fastest CAGR during the forecast period. Preclinical imaging technologies play a crucial role in drug discovery by facilitating the identification and validation of new drug targets, assessing the impact of drug compounds in animal models, and streamlining drug development procedures. These technologies are extensively employed to evaluate the safety, effectiveness, and pharmacokinetics of potential drug candidates before progressing to human clinical trials. Moreover, there is an increasing emphasis on the advancement of personalized medicine in this field. For instance, in March 2023, Eli Lilly and Company revealed that solanezumab, when administered to individuals with amyloid plaque but no clinical signs of Alzheimer's disease (AD), known as the preclinical phase, using PET imaging, did not halt the progression of cognitive decline caused by AD pathology. Solanezumab specifically targets soluble amyloid beta. In participants of the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) study who received the medication, it did not eliminate plaque or prevent amyloid buildup.
By end-user, pharma and biotech companies was the highest revenue-grossing segment in the global Preclinical Imaging Market in 2023 owing to the increasing need for preclinical imaging among biotechnology firms, growing occurrence of infectious diseases, and rising efforts in developing novel therapeutics and vaccines. Additionally, research institutes is predicted to grow at the fastest CAGR during the forecast period owing to the increasing research efforts have led to a heightened demand for procedures such as CT & MRI, among others, within institutes, growing interest among researchers in utilizing imaging modalities to observe alterations in organs, tissues, cells, or at the molecular level in animals, and rising adoption of advanced devices. For instance, in June 2023, Mediso Ltd. has installed its nanoScan 7T MRI system at the University of Milano-Bicocca in Italy. This advanced MRI system features a cryogen-free superconducting magnet. Utilizing the nanoScan 7T MRI system, the University aims to analyze imaging characteristics of preclinical disease models and introduce innovative in vivo diagnostic methods.
North America region is anticipated for the highest revenue share during the forecast period owing to the presence of robust research infrastructure, skilled workforce availability, a substantial number of preclinical initiatives, increased utilization of advanced devices, and growing introduction of novel devices. For instance, in May 2023, Revvity, Inc. introduces an improved imaging lineup aimed at fostering innovation in various preclinical research fields, unveiling three new systems. Among these innovations are the advanced IVIS Spectrum 2 and IVIS SpectrumCT 2 imaging systems, which enhance versatility and sensitivity benchmarks in optical imaging for in vivo applications. Additionally, the QuantumTM GX3 microCT structural imaging solution is launched, boasting enhanced resolution and speed for both in vivo and ex vivo imaging tasks, facilitating research on disease biology and the expedited evaluation of therapeutic candidates. Additionally, Europe region is predicted to grow at fastest CAGR during the forecast period owing to the factors such as reduced research expenses, relaxed regulatory standards, heightened governmental funding for research & development initiatives, and increasing partnerships among industry participants. For instance, in April 2023, Scintica, a prominent provider of advanced preclinical research instruments, has revealed a new partnership with Bioemtech, a firm specializing in desktop SPECT, PET, and optical scanners for preclinical research applications. This collaboration seeks to broaden the accessibility of Bioemtech's preclinical instruments to researchers globally.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Product, Application, and End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
Segmentation: Preclinical Imaging Market Report 2023 - 2034
Preclinical Imaging Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Reagents
- Optical Imaging
- MRI Imaging
- Services
- PET/SPECT Imaging
- CT Imaging
- Ultrasound Imaging
- Photoacoustic Imaging
- Multi-modal Imaging
Preclinical Imaging Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Drug Discovery
- Research and Development
Preclinical Imaging Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Research Institutes
- Pharma and Biotech Companies
- Others
Preclinical Imaging Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Preclinical Imaging Market: Product Estimates & Trend Analysis
8. Preclinical Imaging Market: Application Estimates & Trend Analysis
9. Preclinical Imaging Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Preclinical Imaging Market
12. Europe Global Preclinical Imaging Market
13. Asia Pacific Global Preclinical Imaging Market
14. Latin America Global Preclinical Imaging Market
15. MEA Global Preclinical Imaging Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- VisualSonics Inc. (Fujifilm)
- Bruker Corporation
- Agilent Technologies
- Molecubes
- MR Solutions
- PerkinElmer Inc.
- Siemens A.G.
- Mediso Ltd.
- TriFoil Imaging
- MILabs B.V.
- General Electric (GE)
